Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
A legfontosabb adatok
- Ki végzi
- Johns Hopkins University
- Hol
- Baltimore (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2026. okt. 26.
- Várható befejezés
- 2027. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Biocidin REMOVE
- Placebo
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with irritable bowel syndrome (IBS) who also have too many bacteria in the small intestine (SIBO), shown by a breath test.
- Életkor
- 18 years or older
- Nem
- All sexes can join.
- A betegség stádiuma
- IBS by Rome IV criteria. A lactulose breath test must show SIBO: hydrogen rising more than 20 parts per million above baseline in the first 90 minutes, and/or methane of 10 parts per million or greater. A "flat line pattern" (gas levels 3 parts per million or less, no spikes) is also accepted.
- Korábbi kezelés
- No antibiotics or probiotics within 30 days. No current narcotic use. No chronic steroids or biologics.
- Biomarker vagy leletérték
- Positive lactulose breath test for SIBO, or a flat line pattern on the test.
A részvétel fő kizáró okai
- Negative SIBO breath test at the start
- Restricted diets such as low carbohydrate, gluten-free or low FODMAP
- Celiac disease, inflammatory bowel disease, chronic liver disease or a weak immune system
- Pregnant or breastfeeding
- Insulin-dependent or poorly controlled diabetes (HbA1c greater than 7.0% (53 mmol/mol))
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years or older
- Irritable bowel syndrome by Rome IV criteria with a positive lactulose breath test for small intestinal bacterial overgrowth, defined as a rise of more than 20 parts per million of hydrogen above baseline in the first 90 minutes of testing and/or a methane level of 10 parts per million or greater at any point during the test; OR
- Irritable bowel syndrome by Rome IV criteria with a lactulose breath test showing a "flat line pattern," with exhaled gas levels remaining very low (3 parts per million or less) with no spikes
- Female participants of childbearing age who are sexually active with male partners must agree to use a highly effective method of contraception, such as abstinence, hormonal contraceptive, intrauterine device, or bilateral tubal occlusion
Ki nem vehet részt
- Immunocompromised (chronic steroids, biologics), CD4 less than 400, AIDS not on therapy, neutropenia, acute and chronic leukemia, lymphoma
- Poorly controlled anxiety or depression despite medication
- Concurrent narcotic use
- Confirmed celiac disease
- Portal hypertension
- Diagnosis of inflammatory bowel disease
- COVID-19 positive
- Connective tissue disease such as lupus or scleroderma
- Chronic liver disease, defined as: ICD-10 known diagnoses of chronic liver disease; OR known or suspected liver cirrhosis, portal hypertension, or chronic hepatitis; OR serum AST and ALT elevation greater than 2 times the upper limit of normal with decreased serum albumin less than 4.0 g/dL within the last 6 months
- Insulin dependent or poorly controlled diabetes mellitus (HbA1c greater than 7.0%)
- Negative SIBO breath testing at baseline
- Restricted diets (low carbohydrate, Atkins, gluten-free, low FODMAP, or others)
- Pregnant or breastfeeding
- Untreated significant anxiety or depression
- Unable to provide informed consent
- Antibiotic or probiotic use within 30 days
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Johns Hopkins HospitalBaltimore, Egyesült ÁllamokContact: Lisa DattaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal bacterial overgrowth (SIBO) in adults with irritable bowel syndrome (IBS). SIBO means there are too many bacteria in the small intestine. It can make IBS symptoms worse.
A teljes eredeti leírásKevesebb
This is a small first study, called a pilot study. Its results will help researchers plan larger studies.
The main questions it aims to answer are:
Does Biocidin REMOVE clear SIBO? Does it lower IBS symptoms and improve quality of life? Does it change the mix of bacteria in the gut? Researchers will compare Biocidin REMOVE to a placebo. A placebo is a look-alike capsule that contains no active ingredients. Neither the participants nor the research team will know who gets which one. About 40 adults age 18 and older will take part.
Participants will:
Take capsules by mouth twice a day for about 5 weeks. Participants will start with a low dose and build up to 2 capsules twice a day.
Take a breath test at the start and at the end of treatment. This test checks for SIBO.
Collect a stool sample at home at the start and at the end of treatment. Answer questions about symptoms and quality of life. Report what was eaten during the study. Come back for one check-in about 4 weeks after treatment ends.
A vizsgálat 2 csoportja
- Biocidin REMOVEA vizsgált kezelés
Participants receive Biocidin REMOVE capsules, a herbal preparation supplied as a 665 mg capsule containing 325 mg of the active proprietary blend. Dosing begins with a 9-day titration, increasing by one capsule every three days: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, and two capsules in the morning with one in the evening on Days -3 to -1. Participants reach the target dose of two capsules twice daily on Day 1 and continue at that dose through Day 28. Capsules are identical in appearance to placebo.
- PlaceboPlacebo, összehasonlításként
Participants receive matching placebo capsules, identical in appearance to Biocidin REMOVE and containing no active ingredients. Placebo follows the same 9-day titration and dosing schedule as the experimental arm: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, two capsules in the morning with one in the evening on Days -3 to -1, then two capsules twice daily on Days 1 through 28.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Pilot Study of the Role of an Antimicrobial Herbal Formulation (Biocidin REMOVE) for the Management of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Irritable Bowel Syndrome (IBS)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 16.